Clinigen
Clinigen Group plc, headquartered in the United Kingdom, is a leading global pharmaceutical and services company specialising in the provision of access to medicines. Founded in 2010, Clinigen has rapidly established itself in the healthcare industry, focusing on unlicensed and niche products, clinical trial services, and the management of complex supply chains. With a strong presence in Europe, North America, and Asia, Clinigen offers unique solutions that bridge the gap between pharmaceutical companies and patients. Their core services include the provision of clinical trial supplies and the management of access programmes, ensuring that patients receive critical treatments when they need them most. Clinigen's commitment to patient access and innovative solutions has positioned it as a trusted partner in the global healthcare landscape, achieving significant milestones in expanding its product offerings and market reach.
DitchCarbon Score
How does Clinigen's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Clinigen's score of 25 is lower than 65% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Clinigen's reported carbon emissions
Clinigen, headquartered in the United Kingdom, is committed to achieving net-zero carbon emissions across all scopes by 2050. As of now, there is no specific emissions data available for the most recent year. However, Clinigen has made significant strides in its climate commitments, having officially committed to the Science Based Targets initiative (SBTi) in May 2023. This commitment underscores their dedication to aligning with global climate goals. Clinigen's long-term strategy includes a comprehensive approach to reducing emissions across all scopes, although specific reduction targets have not been detailed. The company is actively working towards integrating sustainability into its operations within the pharmaceuticals, biotechnology, and life sciences sector. By committing to net-zero emissions, Clinigen aims to contribute positively to the global effort against climate change, demonstrating leadership in environmental responsibility within its industry.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Clinigen is committed to some reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
